REPLIGEN CORP (RGEN)
$0.00+$0.00 (+0.00%) TodayExtended Hours
Latest RGEN Insider Trades
Olivier Loeillot - OfficerOpen-market sale$977K
Olivier Loeillot - OfficerOlivier Loeillot - OfficerOlivier Loeillot - OfficerOlivier Loeillot - Officer
Martin D. MadausRepligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia-Pacific contribute about 44%, 37%, and 19% of revenue, respectively.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 3 | 6,689 | $1.16M |
| Option exercise | 2 | 10,852 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
48 Form 4 filings on record, the earliest from Nov 20, 2024, newest first. Filing history page 2 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Olivier Loeillot - Officer | Open-market sale | Common Stock | 7,041 | $170.00 | $1.20M | |
| James Bylund - Officer | Open-market sale | Common Stock | 2,191 | $151.21 | $331K | |
| Anthony Hunt | Open-market sale | Common Stock | 2,100 | $152.17 | $320K | |
| Anthony Hunt | Open-market sale | Common Stock | 2,923 | $153.14 | $448K | |
| Anthony Hunt | Open-market sale | Common Stock | 2,500 | $154.32 | $386K | |
| Anthony Hunt | Open-market sale | Common Stock | 3,000 | $155.45 | $466K | |
| Anthony Hunt | Open-market sale | Common Stock | 5,737 | $156.22 | $896K | |
| Anthony Hunt | Open-market sale | Common Stock | 1,956 | $157.11 | $307K | |
| Anthony Hunt | Option exercise | Stock Option (Right to Buy) | 2,952 | $0.00 | - | |
| Anthony Hunt | Option exercise | Common Stock | 2,952 | $33.87 | $100K | |
| Anthony Hunt | Open-market sale | Common Stock | 1,784 | $151.01 | $269K | |
| Anthony Hunt | Open-market sale | Common Stock | 3,741 | $154.92 | $580K | |
| Anthony Hunt | Open-market sale | Common Stock | 4,740 | $155.85 | $739K | |
| Anthony Hunt | Open-market sale | Common Stock | 4,959 | $156.65 | $777K | |
| Anthony Hunt | Open-market sale | Common Stock | 11,096 | $158.01 | $1.75M | |
| Anthony Hunt | Open-market sale | Common Stock | 464 | $158.51 | $74K | |
| Anthony Hunt | Option exercise | Stock Option (Right to Buy) | 25,000 | $0.00 | - | |
| Anthony Hunt | Option exercise | Common Stock | 25,000 | $33.87 | $847K | |
| Olivier Loeillot - Officer | Tax withholding / forfeiture | Common Stock | 1,248 | $145.23 | $181K | |
| Jason K. Garland - Officer | Tax withholding / forfeiture | Common Stock | 412 | $121.68 | $50K | |
| Anthony Hunt | Option exercise | Common Stock | 20,000 | $33.87 | $677K | |
| Anthony Hunt | Open-market sale | Common Stock | 96 | $116.34 | $11K | |
| Anthony Hunt | Open-market sale | Common Stock | 1,108 | $118.32 | $131K | |
| Anthony Hunt | Open-market sale | Common Stock | 3,262 | $119.64 | $390K | |
| Anthony Hunt | Open-market sale | Common Stock | 14,882 | $120.19 | $1.79M | |
| Anthony Hunt | Open-market sale | Common Stock | 7,584 | $121.42 | $921K | |
| Anthony Hunt | Open-market sale | Common Stock | 2,179 | $122.23 | $266K | |
| Anthony Hunt | Option exercise | Stock Option (Right to Buy) | 20,000 | $0.00 | - | |
| Olivier Loeillot - Officer | Tax withholding / forfeiture | Common Stock | 2,506 | $116.18 | $291K | |
| Violetta Hughes - Officer | Grant or award | Common Stock | 4,142 | $0.00 | - | |
| Violetta Hughes - Officer | Grant or award | Stock Option (Right to Buy) | 3,914 | $0.00 | - | |
| Martin D. Madaus | Open-market purchase | Common Stock | 1,800 | $112.13 | $202K | |
| Karen A. Dawes | Grant or award | Common Stock | 973 | $0.00 | - | |
| Karen A. Dawes | Grant or award | Stock Option (Right to Buy) | 1,800 | $0.00 | - | |
| Glenn P. Muir | Grant or award | Common Stock | 973 | $0.00 | - | |
| Glenn P. Muir | Grant or award | Stock Option (Right to Buy) | 1,800 | $0.00 | - | |
| Nicolas Barthelemy | Grant or award | Common Stock | 973 | $0.00 | - | |
| Nicolas Barthelemy | Grant or award | Stock Option (Right to Buy) | 1,800 | $0.00 | - | |
| Anthony Hunt | Option exercise | Common Stock | 11,808 | $33.87 | $400K | |
| Anthony Hunt | Option exercise | Stock Option (Right to Buy) | 11,808 | $0.00 | - | |
| Anthony Hunt | Option exercise | Common Stock | 24,246 | $33.87 | $821K | |
| Anthony Hunt | Open-market sale | Common Stock | 24,246 | $139.67 | $3.39M | |
| Anthony Hunt | Option exercise | Stock Option (Right to Buy) | 24,246 | $0.00 | - | |
| Olivier Loeillot - Officer | Tax withholding / forfeiture | Common Stock | 861 | $123.41 | $106K | |
| Jason K. Garland - Officer | Tax withholding / forfeiture | Common Stock | 367 | $123.41 | $45K | |
| Glenn P. Muir | Option exercise | Common Stock | 19,000 | $36.29 | $690K | |
| Glenn P. Muir | Option exercise | Stock Option (Right to Buy) | 19,000 | $0.00 | - |
This is as far as the anonymous view goes. Create a free account for all 48 RGEN filings on record.
A Form 144 is notice of an INTENDED sale, not a completed one. It often precedes the Form 4 that reports the trade actually happening.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| Loeillot Olivier | Officer, Director | 5,426 | $977K | View on EDGAR | |
| - | - | - | - | View on EDGAR | |
| - | - | - | - | View on EDGAR |
REPLIGEN CORP (RGEN) had 3 insider filings in the last 90 days, with the most recent on 2026-08-21. The full record for RGEN runs to 48 Form 4 filings, the earliest from 2024-11-20. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of RGEN were filed in the last 90 days. 1 purchase is on record for this company.
3 insider sales of RGEN were filed in the last 90 days, totaling $1.16M.
This page tracks RGEN Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add RGEN to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
